OncoMatch/Clinical Trials/NCT06465069
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Official title: A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors
Is NCT06465069 recruiting? Yes, currently enrolling (Oct 2026). This Phase 1 trial studies multiple treatments including LY4052031 and Pembrolizumab for metastatic solid tumor.
Treatment: LY4052031 · Pembrolizumab — The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Tumor Agnostic
Urothelial Carcinoma
Triple-Negative Breast Cancer
Breast Carcinoma
Non-Small Cell Lung Carcinoma
Esophageal Carcinoma
Pancreatic Cancer
Ovarian Cancer
Cervical Cancer
Head and Neck Squamous Cell Carcinoma
Prostate Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: enfortumab vedotin
Exception: history of Grade ≥3 skin toxicity associated with enfortumab vedotin that required treatment discontinuation
History of Grade ≥3 skin toxicity associated with enfortumab vedotin that required treatment discontinuation
Lab requirements
Cardiac function
Significant cardiovascular disease; QTcF ≥ 470 ms
Significant cardiovascular disease; Prolongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 ms
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope National Medical Center · Duarte, California
- University of California, San Diego (UCSD) - Moores Cancer Center · La Jolla, California
- UCLA Department of Medicine-Hematology/Oncology · Los Angeles, California
- Sarah Cannon Research Institute at HealthOne · Denver, Colorado
- Florida Cancer Specialists and Research Institute · St. Petersburg, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06465069 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior enfortumab vedotin disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify